FOR NEW ZEALAND RESIDENTS
FOR NEW ZEALAND RESIDENTS
Hypothetical patient for illustrative purposes only.
Even if treatment with chemotherapy is successful, many ovarian cancer patients may still see their cancer come back. This is called recurrence, and it can happen even when it seems like you’re in remission. It’s difficult to think about the possibility of ovarian cancer returning, but today, there are options that can help you take action to help delay it. As you discuss any future treatment plans with your doctor, it is important to know your options, one of which is maintenance therapy1.
What
is maintenance therapy?
Maintenance therapy is a treatment given after completing chemotherapy to help extend the time before cancer returns.1
When
should I start talking about maintenance therapy with my healthcare team?
You can talk with your healthcare team before, during, or toward the end of chemotherapy to see if starting maintenance therapy after you respond to chemotherapy is right for you.
Why
do patients choose maintenance therapy?
While each patient has their own reasons, maintenance therapy may be an active step you can take in your ovarian cancer care plan.
Where
does maintenance therapy fit in a treatment plan?
Talking to your healthcare team will give you an idea of where and when maintenance therapy may fit into your individualised treatment plan.
ZEJULA is indicated2:
To help you in a conversation with your doctor about maintenance treatment and whether ZEJULA is right for you, download the attached question guide to take with you to your next oncology appointment.
NOW FULLY FUNDED*1
*Special Authority criteria applies
Any information provided on this website should be discussed with your Health Care Professional and does not replace Health Care Professional advice.
ZEJULA Safety Information:2
- Hypersensitivity to the active substance or any excipients.
- Breast feeding is contraindicated during administration of ZEJULA and for 1 month after receiving the last dose.
Adverse reactions: Very common (≥10%): thrombocytopenia, anaemia, neutropenia. Common (≥ 1/100 to <1/10): Myelodysplastic syndrome/ acute myeloid leukaemia, leukopenia, hypokalemia, hypertension, nausea, vomiting, abdominal pain, fatigue, asthenia, GGT and ALT increased.
References:
By clicking the links, you will be re-directed to a website not owned or monitored by GSK, and GSK is not responsible for the content of that website.
ZEJULA (niraparib: 100mg capsules and tablets) is a prescription medicine used in adults for the treatment of cancer of the ovary, the fallopian tubes or the peritoneum. It is used for the treatment of cancer that has responded to first treatment with platinum-based chemotherapy or come back (recurred) after the cancer has responded to previous treatment with standard platinum-based chemotherapy. ZEJULA is fully funded for the treatment of advanced and recurrent ovarian cancer; Special Authority criteria apply. ZEJULA has risks and benefits and should be initiated and supervised by a doctor experienced in the use of anticancer medicines. Ask your doctor if ZEJULA is right for you. If your symptoms worsen or you have side effects, see your doctor, pharmacist or healthcare professional. Use strictly as directed. Normal doctor charges apply. Additional product information and Consumer Medicine Information (CMI) is available at https://www.medsafe.govt.nz/Consumers/cmi/z/zejula.pdf.
Trademarks are owned by or licensed to the GSK group of companies. ©2025 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
Registered office: Level 12, Aon Centre, 29 Customs Street West, Auckland 1010, New Zealand. Private Bag 106600, Auckland City, New Zealand 1143.
This site is intended for NZ audience only.
TAPS NP23024 PM-NZ-NRP-WCNT-250006 Date of Approval: 09 2025 Date of Expiry: 09 2027
